Navigation Links
CHADS2 risk score assigns over one-third of stroke patients to low or intermediate stroke risk

In contrast, a CHA2DS2-VASc score of 0 identifies a subgroup of patients with very low stroke risk unlikely to benefit from anticoagulation treatment.

Professor Nabauer said: "AF is the most frequent cardiac arrhythmia requiring hospitalisation and has a 1-2% prevalence in the general population. AF is associated with a significant risk of stroke with frequently disabling consequences. While oral anticoagulation is very effective in preventing ischaemic strokes in AF, it increases bleeding risk. Identification of patients with low risk of stroke not requiring oral anticoagulation is important to maximise anticoagulation benefit while avoiding the cost, hassle, and bleeding risk of oral anticoagulation."

The present study tested stroke risk stratification schemes for identifying patients with very low stroke risk who may not benefit from oral anticoagulation. The analysis was based on the prospective registry of the German Competence Network on Atrial Fibrillation (AFNET) which started in 2004-2006 and includes 9,575 patients with AF. Follow-up was for a mean of 5.1 years, and stroke events were adjudicated by a critical event committee.

On enrolment, 47.7% of patients with non-valvular AF (n=8,847) in the AFNET registry were assigned a CHADS2 score of 0 (16.2%) or 1 (31.5%) indicating that oral anticoagulation was not definitively recommended. Surprisingly, 35.8% (145 out of 405) of strokes and other thromboembolic events (transient ischaemic attack, systemic embolism) during follow-up occurred in this patient subgroup initially classified by CHADS2 to have low or intermediate stroke risk (CHADS2=0: 45, CHADS2=1: 100 events).

Professor Nabauer said: "This finding suggests that classes CHADS2 0 and 1 contain subgroups of patients with significant stroke risk that may be identified by refined stroke risk stratification."

The CHA2DS2-VASc score, which adds age 65-74 years, vascular disease and female gender as stroke risk factors to the CHADS2 score, has been put forward to improve risk stratification in patients with low stroke risk and is the recommended risk stratification scheme in the ESC Guidelines on atrial fibrillation.1,2

In the current study, application of the CHA2DS2-VASc score reclassified 53.8% of patients with CHADS2 scores 0 or 1 to a CHA2DS2-VASc score of 2 and higher, where oral anticoagulation is the recommended treatment. Conversely, CHA2DS2-VASc assigned a very low stroke risk score of 0 to 55.6% of patients previously classified as CHADS2=0 (9.0% of all patients).

Professor Nabauer said: "Only 8 strokes and other thromboembolic events were observed in these patients classified as CHA2DS2-VASc=0 during the follow-up period (strokes occurring in association with cardioversion or ablation were excluded). This finding supports the use of CHA2DS2-VASc stroke risk stratification to identify patients at very low stroke risk who may not benefit from oral anticoagulation for ischaemic stroke prevention."

He concluded: "A CHADS2 score of 0 or 1 does not appear to be suitable to identify patients with AF at low risk for stroke while CHA2DS2-VASc picks up these patients. The risk of stroke in patients with a CHA2DS2-VASc score of 0 over a mean follow up of 5.1 years was very low. Our data support the current recommendation that oral anticoagulation is not beneficial in patients with 'lone AF' or a CHA2DS2-VASc score of 0."


Contact: Celine Colas
European Society of Cardiology

Related medicine news :

1. Liberty University Student Scores Among Highest in Nation on Medical School Entrance Exam
2. Natures Tears® EyeMist® Celebrates Perfect Score on
3. New method successfully scores joint damage in rheumatoid arthritis
4. Prompt Alert® Scores Prominent Berth on PROFIT Magazine's 2013 List of Canada's Fastest-Growing Companies
5. Tennis Score Tracker 3.0 Now Available - The Most Advanced Tennis Scorekeeper for the iPhone, iPad, iPod touch, with Detailed Statistics, Live Scoring, 20+ New Features
6. Mirena IUD Lawsuit Update: Supreme Court of New Jersey Centralizes Litigation; Parker Waichman LLP Underscores the Advantages of this Decision
7. Top 2013 Idaho Home Security Alarm System Companies Scored by
8. 7 Mile Bridge Death Underscores Victim Rights
9. DCIS Score quantifies risk of IBE
10. Best 2013 Colorado Burglar Alarm System Companies Scored by
11. Best 2013 California Home alarm System Companies Scored by
Post Your Comments:
(Date:11/30/2015)... VA (PRWEB) , ... November 30, 2015 , ... ... Research Foundation (Meso Foundation) released information for caregivers and held two webinars on ... are available on demand free of charge at . , With ...
(Date:11/30/2015)... Irving, TX (PRWEB) , ... November 30, 2015 ... ... for plastic surgery and dermatology, is proud to announce that its ThermiRFR temperature ... Europe. , ThermiRF is an innovative multi-application radiofrequency platform which uses temperature as ...
(Date:11/30/2015)... ... November 30, 2015 , ... The Museum of ... ushering in a new era of publicly accessible automated technology. Now, by popular ... to offer guests an up-close look at the shuttle at MOSI’s main entrance. ...
(Date:11/30/2015)... ... November 30, 2015 , ... On Saturday, October 24th, 2015, at ... an annual fundraising event, a 5K walk known as “Making Strides Against Breast Cancer”. ... abuse which is also located in Battle Creek, joined in for this campaign that ...
(Date:11/30/2015)... ... 2015 , ... During the week of Thanksgiving, the Mesothelioma ... its research, education, support, and advocacy efforts. The campaign is held every year-end ... Applied Research Foundation, which also goes by Meso Foundation, holds the highest ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015  QT Vascular Ltd., ... and together with its subsidiaries, TriReme Medical LLC and ... company engaged in the design, assembly and distribution of ... vascular disease, is pleased to announce that a three-judge ... Court of Appeals for the Federal Circuit ("Federal Circuit") ...
(Date:11/30/2015)... Nov. 30, 2015  DURECT Corporation (Nasdaq: ... Matt Hogan , Chief Financial Officer, will ... on Tuesday, December 8 at 2:45 pm ... at the Westin Grand Central Hotel in ... for one-on-one meetings at this conference; interested ...
(Date:11/30/2015)... DUBLIN , Nov. 30, 2015 ... addition of the "Orphan Drugs Market 2015-2019" ... ) has announced the addition of the ... their offering. --> Research and Markets ... the "Orphan Drugs Market 2015-2019" report ...
Breaking Medicine Technology: